Peyronie’s Disease Treatment Market Analysis and Forecast to 2027 By Recent Trends, Developments in Regional Growth Overview

What is Peyronie's disease?

Peyronie's disorder is a condition where scar tissue builds up around the head of the erection part, making erections painful and highly unlikely. Peyronie's disorder also appears to be more common in men who have a family history of such problems as diabetes, heart disease, and atherosclerosis (the buildup of cholesterol, fat, and other material around arteries). It has also been found to be more common in men who are obese or have low muscle mass. The scar tissue that forms can cover an area of about two square inches on the shaft or about twenty-five millimeters on an average shaft.

Direct Purchase the Peyronie's disease treatment Market Report at: https://www.coherentmarketinsights.com/promo/buynow/61

Global Peyronie's disease treatment market is witnessing fastest growth in North America region

Growing number of studies and clinical trials associated with Peyronie’s disease is expected to expand size of the Peyronie's disease treatment market. For example, in July 2019, The Journal of Sexual Medicine of the International Society for Sexual Medicine published a study ‘The Effectiveness of 3-D Computed Tomography in the Evaluation of Deformities in Patients with Peyronie's Disease: A Pilot Study, which concluded that computed tomography failed to provide more information than the evaluation with combined intracavernous injection stimulation test and current limitations and cost increases limit the use of 3D computed tomography in the assessment of Peyronie’s disease. Moreover, most of the healthcare associations are coming up with new guidelines about the treatment of Peyronie's disease which is further projected to augment growth of the Peyronie's disease treatment market. For example, in 2018, the Canadian Urological Association (CUA) presented new guidelines recommending the use of remodeling techniques based on Traction Device of Andromedical (ANDROPEYRONIE) in combination with collagenase injections for the treatment of patients with Peyronie's disease.

Get PDF Brochure for Research Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/61

In April 2018, Paladin Labs Inc., a subsidiary of Endo International plc announced the launch of a new indication for XIAFLEX® (collagenase clostridium histolyticum), the first and only Health Canada-approved treatment for appropriate patients with Peyronie's Disease

North America is expected to hold a dominant position in the global Peyronie's disease treatment market over the forecast period owing to the increasing prevalence of a rare disease in the region. According to the National Institutes of Health, around 1 in 100 men in the United States over the age of 18 have been diagnosed with Peyronie's disease. However, based on studies of men who reported having symptoms of Peyronie's disease, researchers estimate that the actual number of men who have Peyronie's disease is more than 1 in 10.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.